Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04786600 · ClinicalTrials.gov registry record · Phase 2
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
A Phase 2 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04786600 is a Phase 2 study that was terminated before completion, run by University of Florida. The registered enrollment target is 6 participants.
The verdict
NCT04786600, a Phase 2 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer. The aim of this study will be to measure and compare the overall survival, progression-free survival, and best overall response while on study of patients whose treatment has been guided by these two approaches.
Interventions
- DEVICE Signatera ctDNA assay
- DRUG pre-specified sequence of FDA-approved drugs and drug combinations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2024-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04786600
The ClinicalTrials.gov registry entry for NCT04786600 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Signatera ctDNA assay is the first listed.
NCT04786600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04786600 about?
NCT04786600 is a clinical study titled "A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial". This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer. The aim of this study will be to measure and compare the overall survival, progression-free survival, and bes...
What is the current status of trial NCT04786600?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2022-03-14. Estimated completion is 2024-03-19.
What interventions are being tested in trial NCT04786600?
The interventions under investigation include: Signatera ctDNA assay (DEVICE), pre-specified sequence of FDA-approved drugs and drug combinations (DRUG).
Who is sponsoring clinical trial NCT04786600?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.